317 related articles for article (PubMed ID: 29378962)
1. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G
Zhu D; Xu S; Deyanat-Yazdi G; Peng SX; Barnes LA; Narla RK; Tran T; Mikolon D; Ning Y; Shi T; Jiang N; Raymon HK; Riggs JR; Boylan JF
Mol Cancer Ther; 2018 Aug; 17(8):1727-1738. PubMed ID: 29866747
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.
Zheng L; Chen Z; Kawakami M; Chen Y; Roszik J; Mustachio LM; Kurie JM; Villalobos P; Lu W; Behrens C; Mino B; Solis LM; Silvester J; Thu KL; Cescon DW; Rodriguez-Canales J; Wistuba II; Mak TW; Liu X; Dmitrovsky E
Mol Cancer Ther; 2019 Oct; 18(10):1775-1786. PubMed ID: 31358662
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
Szymiczek A; Carbone M; Pastorino S; Napolitano A; Tanji M; Minaai M; Pagano I; Mason JM; Pass HI; Bray MR; Mak TW; Yang H
Oncogene; 2017 Nov; 36(46):6501-6507. PubMed ID: 28759042
[TBL] [Abstract][Full Text] [Related]
7. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
[TBL] [Abstract][Full Text] [Related]
8. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
Riggs JR; Nagy M; Elsner J; Erdman P; Cashion D; Robinson D; Harris R; Huang D; Tehrani L; Deyanat-Yazdi G; Narla RK; Peng X; Tran T; Barnes L; Miller T; Katz J; Tang Y; Chen M; Moghaddam MF; Bahmanyar S; Pagarigan B; Delker S; LeBrun L; Chamberlain PP; Calabrese A; Canan SS; Leftheris K; Zhu D; Boylan JF
J Med Chem; 2017 Nov; 60(21):8989-9002. PubMed ID: 28991472
[TBL] [Abstract][Full Text] [Related]
9. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis underlying resistance to Mps1/TTK inhibitors.
Koch A; Maia A; Janssen A; Medema RH
Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
[TBL] [Abstract][Full Text] [Related]
11. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
12. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
[TBL] [Abstract][Full Text] [Related]
13. High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.
Anderhub SJ; Mak GW; Gurden MD; Faisal A; Drosopoulos K; Walsh K; Woodward HL; Innocenti P; Westwood IM; Naud S; Hayes A; Theofani E; Filosto S; Saville H; Burke R; van Montfort RLM; Raynaud FI; Blagg J; Hoelder S; Eccles SA; Linardopoulos S
Mol Cancer Ther; 2019 Oct; 18(10):1696-1707. PubMed ID: 31575759
[TBL] [Abstract][Full Text] [Related]
14. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
[TBL] [Abstract][Full Text] [Related]
15. The Spindle Assembly Checkpoint Is Not Essential for Viability of Human Cells with Genetically Lowered APC/C Activity.
Wild T; Larsen MS; Narita T; Schou J; Nilsson J; Choudhary C
Cell Rep; 2016 Mar; 14(8):1829-40. PubMed ID: 26904940
[TBL] [Abstract][Full Text] [Related]
16. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
[TBL] [Abstract][Full Text] [Related]
17. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
18. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
19. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
[TBL] [Abstract][Full Text] [Related]
20. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
Wang S; Zhang M; Liang D; Sun W; Zhang C; Jiang M; Liu J; Li J; Li C; Yang X; Zhou X
Eur J Med Chem; 2019 Aug; 175():247-268. PubMed ID: 31121430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
